Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.56 |
| ▸ | PLK1 | P53350 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643050 | 0.91 | NR1H4 (0.55) | NR1H4PLK1THRBTP53MAPT | |
| SCHEMBL643881 | 0.88 | NR1H4 (0.61) | NR1H4PLK1THRBTP53MAPT | |
| SCHEMBL641436 | 0.86 | NR1H4 (0.58) | NR1H4PLK1THRBTP53MAPT | |
| SCHEMBL642508 | 0.84 | NR1H4 (0.54) | NR1H4PLK1THRBTP53MAPT | |
| SCHEMBL642997 | 0.83 | NR1H4 (0.61) | NR1H4PLK1THRBTP53MAPT | |
| SCHEMBL642217 | 0.82 | PLK1 (0.55) | NR1H4PLK1MAPTRARBPPARA | |
| SCHEMBL642660 | 0.82 | LMNA (0.47) | NR1H4PLK1MAPTRARBPPARA | |
| SCHEMBL641663 | 0.82 | NR1H4 (0.62) | NR1H4PLK1THRBTP53MAPT | |
| SCHEMBL642459 | 0.81 | NR1H4 (0.52) | NR1H4PLK1THRBTP53MAPT | |
| SCHEMBL644605 | 0.80 | LMNA (0.51) | NR1H4PLK1TP53MAPTRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057173-B1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | claimed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | claimed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | claimed |
| EP-2057173-A1 | AMIDES AS SPHINGOMYELINE INHIBITORS | Novartis AG (CH) | 2009-05-13 | — | — | EP | claimed |
| WO-2008022771-A1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | claimed |
| EP-2057173-B1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022482-A1 | aSMase inhibitors | SMPD1, SMPD3, SMPD2 | NR1H4 984/4885PLK1 1883/4885THRB 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.